|
|
|
|
|
24.11.25 - 17:06
|
Spago Nanomedical Announces Outcome of Oversubscribed Rights Issue (Accesswire)
|
|
|
NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH ......
|
|
|
07.11.25 - 09:18
|
The Subscription Period in Spago Nanomedical′s Rights Issue Begins Today (Accesswire)
|
|
|
NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH ......
|
|
|
29.10.25 - 09:06
|
Spago Nanomedical Resolves on a Rights Issue of Approximately SEK 25 million to Advance Tumorad (Accesswire)
|
|
|
NOT INTENDED FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH ......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04.04.25 - 08:42
|
BioStock: Spago on the increased dose in Tumorad-01 (Cision)
|
|
|
In March, Spago Nanomedical announced that the independent Data Monitoring Committee had recommended a dose escalation in the ongoing phase I/IIa study with the company's cancer drug candidate. This marks an important step in the study, which Paul Hargreaves, CDO at Spago Nanomedical, discusses further in an interview with BioStock.
See the interview at biostock.se:
https://www.biostock.se/en/2025/04/spago-on-the-increased-dose-in-tumorad-01/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se...
|
|
|
|
|
06.03.25 - 09:54
|
BioStock: Spago takes Tumorad-01 study to the next level (Cision)
|
|
|
Spago Nanomedical has increased the dose of its cancer drug candidate [177]Lu-SN201 in its phase I/IIa Tumorad-01 study, following a recommendation from the independent Data Monitoring Committee. The decision stems from data on six patients across two cohorts with five different cancer types, all showing a satisfactory safety profile. This step keeps Spago on course to complete the phase I part in 2025.
Read the article at biostock.se:
https://www.biostock.se/en/2025/03/spago-takes-tumorad-01-study-to-the-next-level/
This is a press release from BioStock - Connecting Innovation and Capital....
|
|
|
|
|
|
|
|
|
19.12.24 - 10:30
|
BioStock: Spago′s CEO: “We want to expand cancer treatment with effective radiopharmaceuticals” (Cision)
|
|
|
2024 has marked a defining chapter for Spago Nanomedical, solidifying its position in radionuclide therapy. By focusing its energy on the lead Tumorad programme, the company achieved important milestones during the year. BioStock has spoken with CEO Mats Hansen to have him reflect on the past year and look ahead to 2025.
Read the interview with Mats Hansen at biostock.se:
https://www.biostock.se/en/2024/12/spagos-ceo-we-want-to-expand-cancer-treatment-with-effective-radiopharmaceuticals/
This is a press release from BioStock - Connecting Innovation and Capital. https://www.biostock.se/en/...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
